US equities |
TSLA $362.44 ▲+0.00% MU $931.24 ▲+0.00% SPCX $148.62 ▲+0.00% SNDK $1,394.83 ▲+0.00% SKHY $146.11 ▲+0.00% NVDA $217.23 ▲+0.00% AMD $562.23 ▲+0.00% INTC $95.22 ▼-0.16%
FinancialContent

Tharimmune, Inc. - Common Stock (NQ:THAR)

4.740 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tharimmune, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
From Tharimmune, Inc.
Via Business Wire
News headline image
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Via ACCESS Newswire
News headline image
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Via ACCESS Newswire
News headline image
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Via ACCESS Newswire
News headline image
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Via ACCESS Newswire
News headline image
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
Via ACCESS Newswire
News headline image
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Via ACCESS Newswire
News headline image
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
News headline image
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Via ACCESS Newswire
News headline image
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Via ACCESS Newswire
News headline image
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Via ACCESS Newswire
News headline image
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
News headline image
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Via ACCESS Newswire
News headline image
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Via ACCESS Newswire
News headline image
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Via ACCESS Newswire
News headline image
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Via ACCESS Newswire
News headline image
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Via ACCESS Newswire
News headline image
Tharimmune to Present at the Microcap Conference 2025
Via ACCESS Newswire
News headline image
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Via ACCESSWIRE
News headline image
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Via ACCESSWIRE
News headline image
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
News headline image
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Via ACCESSWIRE
News headline image
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Via ACCESSWIRE
News headline image
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
News headline image
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
News headline image
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
News headline image
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Via ACCESSWIRE
News headline image
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Via ACCESSWIRE
News headline image
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Via ACCESSWIRE
< Previous 1 2 Next >